150 related articles for article (PubMed ID: 15997921)
1. The prognostic value of adhesion molecule CD44v6 in women with primary breast carcinoma: a clinicopathologic study.
Ma W; Deng Y; Zhou L
Clin Oncol (R Coll Radiol); 2005 Jun; 17(4):258-63. PubMed ID: 15997921
[TBL] [Abstract][Full Text] [Related]
2. CD44v6 expression in primary breast carcinoma in western India: a pilot clinicopathologic study.
Shah NG; Trivedi TI; Vora HH; Patel KC; Tankshali R; Goswami JV; Shukla SN; Shah PM
Tumori; 2010; 96(6):971-7. PubMed ID: 21388061
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7-8 in human breast cancer.
Tempfer C; Lösch A; Heinzl H; Häusler G; Hanzal E; Kölbl H; Breitenecker G; Kainz C
Eur J Cancer; 1996 Oct; 32A(11):2023-5. PubMed ID: 8943691
[TBL] [Abstract][Full Text] [Related]
4. CD44v6 is not a prognostic factor in primary breast cancer.
Jansen RH; Joosten-Achjanie SR; Arends JW; Volovics A; Hupperets PS; Schouten HC; Hillen HF
Ann Oncol; 1998 Jan; 9(1):109-11. PubMed ID: 9541692
[TBL] [Abstract][Full Text] [Related]
5. CD44 splice variants as prognostic markers in colorectal cancer.
Wielenga VJ; van der Voort R; Mulder JW; Kruyt PM; Weidema WF; Oosting J; Seldenrijk CA; van Krimpen C; Offerhaus GJ; Pals ST
Scand J Gastroenterol; 1998 Jan; 33(1):82-7. PubMed ID: 9489913
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of CD44s and CD44v6 expression in stage two breast carcinoma: an immunohistochemical study.
Morris SF; O'Hanlon DM; McLaughlin R; McHale T; Connolly GE; Given HF
Eur J Surg Oncol; 2001 Sep; 27(6):527-31. PubMed ID: 11520083
[TBL] [Abstract][Full Text] [Related]
7. Combined preoperative CEA and CD44v6 improves prognostic value in patients with stage I and stage II colorectal cancer.
Chen L; Jiang B; Wang Z; Liu M; Yang H; Xing J; Zhang C; Yao Z; Zhang N; Cui M; Su X
Clin Transl Oncol; 2014 Mar; 16(3):285-92. PubMed ID: 23860725
[TBL] [Abstract][Full Text] [Related]
8. CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma.
Bartakova A; Michalova K; Presl J; Vlasak P; Kostun J; Bouda J
J Obstet Gynaecol; 2018 Jan; 38(1):110-114. PubMed ID: 28816557
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of immunohistochemically detected CD44v3 and CD44v6 expression in patients with surgically staged vulvar carcinoma: a multicenter study.
Hefler LA; Concin N; Mincham D; Thompson J; Swarte NB; van Eijkeren MA; Sie-Go DM; Hammond I; McCartney AJ; Tempfer CB; Speiser P
Cancer; 2002 Jan; 94(1):125-30. PubMed ID: 11815968
[TBL] [Abstract][Full Text] [Related]
10. [Expression and clinical significance of adhesive molecule CD44v6 in breast invasive ductal carcinoma].
Lian ZQ; Yang MT; Hou JH; Luo RZ; Wang X; Tang J
Ai Zheng; 2006 Oct; 25(10):1291-5. PubMed ID: 17059779
[TBL] [Abstract][Full Text] [Related]
11. Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis.
Ropponen KM; Eskelinen MJ; Lipponen PK; Alhava E; Kosma VM
Scand J Gastroenterol; 1998 Mar; 33(3):301-9. PubMed ID: 9548625
[TBL] [Abstract][Full Text] [Related]
12. CD44V6 in gastric carcinoma: a marker of tumor progression.
Xin Y; Grace A; Gallagher MM; Curran BT; Leader MB; Kay EW
Appl Immunohistochem Mol Morphol; 2001 Jun; 9(2):138-42. PubMed ID: 11396631
[TBL] [Abstract][Full Text] [Related]
13. CD44 is an independent prognostic factor in early-stage cervical cancer.
Speiser P; Wanner C; Tempfer C; Mittelböck M; Hanzal E; Bancher-Todesca D; Gitsch G; Reinthaller A; Kainz C
Int J Cancer; 1997 Apr; 74(2):185-8. PubMed ID: 9133453
[TBL] [Abstract][Full Text] [Related]
14. Role of CD44 in nonpalpable T1a and T1b breast cancer.
Lyzak JS; Yaremko ML; Recant W; Baunoch DA; Joseph L
Hum Pathol; 1997 Jul; 28(7):772-8. PubMed ID: 9224743
[TBL] [Abstract][Full Text] [Related]
15. CD44 Variant 6 as a Predictive Biomarker for Distant Metastasis in Patients With Epithelial Ovarian Cancer.
Motohara T; Fujimoto K; Tayama S; Narantuya D; Sakaguchi I; Tashiro H; Katabuchi H
Obstet Gynecol; 2016 Jun; 127(6):1003-1011. PubMed ID: 27159753
[TBL] [Abstract][Full Text] [Related]
16. Expression of CD44 variant isoforms and association to the benign form of endocrine pancreatic tumours.
Imam H; Eriksson B; Oberg K
Ann Oncol; 2000 Mar; 11(3):295-300. PubMed ID: 10811495
[TBL] [Abstract][Full Text] [Related]
17. Expression of CD44v6 has no prognostic value in patients with colorectal cancer.
Jüngling B; Menges M; Goebel R; Wittig BM; Weg-Remers S; Pistorius G; Schilling M; Bauer M; König J; Zeitz M; Stallmach A
Z Gastroenterol; 2002 Apr; 40(4):229-33. PubMed ID: 11961731
[TBL] [Abstract][Full Text] [Related]
18. Altered CD44 variant 6 expression in FIGO stage IB cervical carcinoma.
Ayhan A; Baykal C; Al A; Ayhan A
Gynecol Oncol; 2001 Dec; 83(3):569-74. PubMed ID: 11733974
[TBL] [Abstract][Full Text] [Related]
19. Cytosol concentrations of CD44 isoforms in breast cancer tissue.
Hefler L; Tempfer C; Haeusler G; Kucera E; Mayerhofer K; Zeillinger R; Reinthaller A; Kainz C
Int J Cancer; 1998 Oct; 79(5):541-5. PubMed ID: 9761127
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological significance of fascin and CD44v6 expression in endometrioid carcinoma.
Gun BD; Bahadir B; Bektas S; Barut F; Yurdakan G; Kandemir NO; Ozdamar SO
Diagn Pathol; 2012 Jul; 7():80. PubMed ID: 22784357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
